


CLAIMS

1) A compound of formula (I):



wherein:

- G is a COOH group or a tetrazolyl group;
- R1 and R2 are independently selected from hydrogen atoms and alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkenyl, cycloalkenylalkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, or heteroarylalkynyl groups; or R1 and R2 form, together with the nitrogen atom to which they are attached, either a 3- to 14- membered monocyclic or polycyclic heterocyclic ring system or a 5- to 14-membered heteroaryl group wherein said groups comprise from 1 to 5 heteroatoms selected from nitrogen, oxygen and sulphur;
- wherein said alkyl, alkenyl, and alkynyl groups or moieties are unsubstituted or substituted with one to four substituents, which may be the same or different and are independently selected from Ra;
- and wherein said cycloalkyl, heterocyclyl, aryl and heteroaryl groups or moieties are unsubstituted or substituted with one to four substituents, which may be the same or different and are independently selected from Rb;
- R3 and R4 are independently selected from hydrogen atoms and alkyl groups having from 1 to 6 carbon atoms;

- R5 is selected from the group consisting of 6- to 14- membered monocyclic or polycyclic aryl groups and 5- to 14- membered monocyclic or polycyclic heteroaryl groups comprising from 1 to 5 heteroatoms selected from nitrogen, oxygen and sulphur;

wherein said aryl and heteroaryl groups or moieties are unsubstituted or substituted with one to four substituents, which may be the same or different and are independently selected from Rb;

- R6 is a group selected from -OH, -ORc, -NO<sub>2</sub>, halogen, -S(O)Rc, -S(O)<sub>2</sub>Rc, -SRc, -S(O)<sub>2</sub>ORc, -S(O)NRcRc, -S(O)<sub>2</sub>NRcRc, -NRcRc, -O(CRcRc)mNRcRc, -C(O)Rc, -CO<sub>2</sub>Rc, -CO<sub>2</sub>(CRcRc)mCONRcRc, -OC(O)Rc, -CN, -C(O)NRcRc, -NRcC(O)Rc, -OC(O)NRcRc, -NRcC(O)ORc, -NRcC(O)NRcRc, -CRc(N-ORc), -CFH<sub>2</sub>, -CF<sub>2</sub>H, -Ra, -CF<sub>3</sub>, alkyl, alkenyl and alkynyl;

- n is an integer from 0 to 3

- Ra is a group selected from alkyl, -OH, -ORc, -NO<sub>2</sub>, halogen, -S(O)Rc, -S(O)<sub>2</sub>Rc, -SRc, -S(O)<sub>2</sub>ORc, S(O)NRcRc, -S(O)<sub>2</sub>NRcRc, -NRcRc, -O(CRcRc)mNRcRc, -C(O)Rc, -CO<sub>2</sub>Rc, -CO<sub>2</sub>(CRcRc)mCONRcRc, -OC(O)Rc, -CN, -C(O)NRcRc, -NRcC(O)Rc, -OC(O)NRcRc, -NRcC(O)ORc, -NRcC(O)NRcRc, -CRc(N-ORc), -CFH<sub>2</sub>, -CF<sub>2</sub>H, -Ra, or -CF<sub>3</sub>; wherein if two or more Rc groups are present these may be the same or different;

- Rb is a group selected from -OH, -ORD, -NO<sub>2</sub>, halogen, -S(O)Rd, -S(O)<sub>2</sub>Rd, -SRd, -S(O)<sub>2</sub>ORD, -S(O)NRdRd, -S(O)<sub>2</sub>NRdRd, -NRdRd, -O(CRdRd)mNRdRd, -C(O)Rd, -CO<sub>2</sub>Rd, -CO<sub>2</sub>(CRdRd)mCONRdRd, -OC(O)Rd, -CN, -C(O)NRdRd, -NRdC(O)Rd, -OC(O)NRdRd, -NRdC(O)ORD, -NRdC(O)NRdRd, -CRd(N-ORD), -CFH<sub>2</sub>, -CF<sub>2</sub>H, -Ra, -CF<sub>3</sub>, alkyl, alkenyl, C<sub>2-4</sub>alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups or moieties are unsubstituted or substituted with one to four substituents which may be the same or different and are independently selected from Ra;

- 64 -

- L1 is either a direct bond or a group selected from the group consisting of -N(Rc)-, -O-, -N(Rc)CO-, -CON(Rc)-, -O(CO)N(Rc)- and -N(Rc)(CO)O-;
- Rc is a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms;
- Rd is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkenyl, cycloalkenylalkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, or heteroarylalkynyl;  
wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl groups are unsubstituted or substituted with one to four substituents, which may be the same or different and are independently selected from Re;
- Re is a group selected from alkyl, -OH, -ORc, -NO<sub>2</sub>, halogen, -S(O)Rc, -S(O)<sub>2</sub>Rc, -SRc, -S(O)<sub>2</sub>ORc, -S(O)NRcRc, -S(O)<sub>2</sub>NRcRc, -NRcRc, -O(CRcRc)mNRcRc, -C(O)Rc, -CO<sub>2</sub>Rc, -CO<sub>2</sub>(CRcRc)mCONRcRc, -OC(O)Rc, -CN, -C(O)NRcRc, -NRcC(O)Rc, -OC(O)NRcRc, -NRcC(O)ORc, -NRcC(O)NRcRc, -CRc(N-ORc), -CFH<sub>2</sub>, -CF<sub>2</sub>H, -Ra, or -CF<sub>3</sub>; wherein if two or more Rc groups are present these may be the same or different;

and any pharmaceutically acceptable salt thereof as well as any compound resulting from the esterification, with any alcohol, of the carboxylic group in the case where G is such a carboxylic group and any pharmaceutically acceptable salt thereof

- 2) A compound according to claim 1 wherein G is a COOH group as well as any compound resulting from the esterification, with an alcohol, of the COOH group.
- 3) A compound according to any preceding claim wherein R3 and R4 are hydrogen atoms.
- 4) A compound according any preceding claim wherein R1 and R2 are independently selected from hydrogen atoms and alkyl, cycloalkyl, heterocyclylalkyl, aryl, arylalkyl,

heteroarylalkyl groups, wherein said alkyl, alkenyl, and alkynyl, cycloalkyl, heterocycl, aryl and heteroaryl groups or moieties are unsubstituted or substituted;

or R1 and R2 form, together with the nitrogen atom to which they are attached, either a 5- to 8- membered monocyclic heterocyclic ring system wherein said ring system comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur and is unsubstituted or substituted.

- 5) A compound according to any preceding claim wherein R5 is selected from the group consisting of 6- to 14- membered monocyclic or polycyclic aryl and 5- to 14-membered monocyclic or polycyclic heteroaryl groups comprising from 1 to 5 heteroatoms selected from nitrogen, oxygen and sulphur wherein said aryl and heteroaryl groups or moieties are unsubstituted or substituted.
- 6) A compound according to claim 5 wherein said aryl or heteroaryl groups are unsubstituted or substituted by one or more halogen atoms.
- 7) A compound according to any preceding claim wherein L1 is a group selected from -NH-, -O- and -NHCO-.
- 8) A compound according to any preceding claim wherein R5-L1- is selected from the group comprising benzamide, isonicotinamide, 2,6-naphthyridin-1-ylamino, 2,7-naphthyridin-1-ylamino; 2,6-naphthyridin-1-yloxy and 2,7-naphthyridin-1-yloxy wherein said groups are unsubstituted or substituted.
- 9) A compound according to any preceding claim wherein n is zero.
- 10) A compound according to any preceding claim which is one of:
  - (2S)-2-{[(tert-butylamino)sulfonyl]amino}-3-[4-[(3,5-dichloroisocinloyl)amino]phenyl]propionic acid
  - Methyl (2S)-2-(N-benzylaminosulfonilamino)-3-[4-(2,6-dichlorobenzoylamino)phenyl]propionate
  - (2S)-2-(N-benzylaminosulfonilamino)-3-[4-(2,6-dichlorobenzoylamino)phenyl]propionic acid

- Methyl (2S)-3-{4-[{(2,6-dichlorobenzoyl)amino]phenyl}-2-  
{[(dimethylamino)sulfonyl]amino} propionate
- (2S)-3-{4-[{(2,6-dichlorobenzoyl)amino]phenyl}-2-  
{[(dimethylamino)sulfonyl]amino} propionic acid
- Methyl (2S)-3-{4-[{(3,5-dichloroisonicotinoyl)amino]phenyl}-2-  
{[(dimethylamino)sulfonyl]amino}propionate
- (2S)-3-{4-[{(3,5-dichloroisonicotinoyl)amino]phenyl}-2-  
{[(dimethylamino)sulfonyl]amino}propionic acid
- Methyl (2S)-3-(4-{[1-(2,6-dichlorophenyl)methanoyl]amino}phenyl)-2-(piperidine-1-  
sulfonylamino)propionate
- (2S)-3-(4-{[1-(2,6-dichlorophenyl)methanoyl]amino}phenyl)-2-(piperidine-1-  
sulfonylamino)propionic acid
- Methyl (2S)-3-{4-[{(3,5-dichloroisonicotinoyl)amino]phenyl}-2-  
{[(diisobutylamino)sulfonyl]amino}propionate
- (2S)-3-{4-[{(3,5-dichloroisonicotinoyl)amino]phenyl}-2-  
{[(diisobutylamino)sulfonyl]amino}propionic acid
- Methyl (2S)-2-({[benzyl(ethyl)amino]sulfonyl}amino)-3-{4-[{(3,5-  
dichloroisonicotinoyl)amino]phenyl}propionate
- (2S)-2-{[(benzylethylamino)sulfonyl]amino}-3-{4-[{(3,5-  
dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2S)-3-{4-[{(3,5-dichloroisonicotinoyl)amino]phenyl}-2-  
{[(dibutylamino)sulfonyl]amino}propionate
- (2S)-3-{4-[{(3,5-dichloroisonicotinoyl)amino]phenyl}-2-  
{[(dibutylamino)sulfonyl]amino}propionic acid
- Methyl (2S)-3-{4-[{(3,5-dichloroisonicotinoyl)amino]phenyl}-2-  
{[(2-(3,4-dimethoxyphenyl)ethyl)isobutylamino]sulfonyl}amino}propionate
- (2S)-3-{4-[{(3,5-dichloroisonicotinoyl)amino]phenyl}-2-  
{[(2-(3,4-dimethoxyphenyl)ethyl)isobutylamino]sulfonyl}amino}propionic acid
- Methyl (2S)-2-({[bis(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[{(3,5-  
dichloroisonicotinoyl)amino]phenyl}propionate
- (2S)-2-({[bis(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[{(3,5-  
dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2S)-3-{4-[{(3,5-dichloroisonicotinoyl)amino]phenyl}-2-  
{[(methyl(2-pyridin-2-ylethyl)amino]sulfonyl}amino}propionate

- (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(methyl(2-pyridin-2-ylethyl)amino)sulfonyl]amino}propionic acid
- Methyl (2S)-2-{[(cyclohexylmethylamino)sulfonyl]amino}-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2S)-2-{[(cyclohexylmethylamino)sulfonyl]amino}-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(3-methylbutyl)(thien-2-ylmethyl)amino}sulfonyl]amino}propionate
- (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(3-methylbutyl)(thien-2-ylmethyl)amino}sulfonyl]amino}propionic acid
- Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(piperidin-1-ylsulfonyl)amino}propionate
- (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(piperidin-1-ylsulfonyl)amino}propionic acid
- Methyl (2S)-2-[(azepan-1-ylsulfonyl)amino]-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2S)-2-[(azepan-1-ylsulfonyl)amino]-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(morpholin-4-ylsulfonyl)amino}propionate
- (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(morpholin-4-ylsulfonyl)amino}propionic acid
- Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(thiomorpholin-4-ylsulfonyl)amino}propionate
- (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(thiomorpholin-4-ylsulfonyl)amino}propionic acid
- Methyl (2S)-2-{[(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate
- (2S)-2-{[(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid
- Methyl (2S)-2-{[(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate
- (2S)-2-{[(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid


- Methyl (2S)-2-{{(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate}
- (2S)-2-{{(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid}
- Methyl (2S)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}-2-{{(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionate}
- (2S)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}-2-{{(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionic acid}
- Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{{(diisopropylamino)sulfonyl]amino}propionate}
- (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{{(diisopropylamino)sulfonyl]amino}propionic acid}
- Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{{(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionate}
- (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{{(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionic acid}
- Methyl (2S)-2-{{(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate}
- (2S)-2-{{(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid}
- Methyl (2S)-2-{{(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate}
- (2S)-2-{{(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid}
- Methyl (2S)-2-({{[cyclohexyl(isopropyl)amino]sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate}
- (2S)-2-({{[cyclohexyl(isopropyl)amino]sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid}
- Methyl (2S)-2-{{(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate}
- (2S)-2-{{(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid}
- Methyl (2S)-2-{{(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate}

- (2S)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid
- Methyl (2S)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate
- (2S)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid
- Methyl (2S)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate
- (2S)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid
- Methyl (2S)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}propionate
- (2S)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}propionic acid
- Methyl (2S)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2S)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2S)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2S)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid
- Methyl (2S)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichlorobenzoyl)amino]phenyl}propionate
- (2S)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichlorobenzoyl)amino]phenyl}propionic acid
- Methyl (2S)-3-{4-[(2,6-dichloroisonicotinoyl)amino]phenyl}-2-({[isobutyl[(1S)-1-phenylethyl]amino]sulfonyl}amino)propionate
- (2S)-3-{4-[(2,6-dichloroisonicotinoyl)amino]phenyl}-2-({[isobutyl[(1S)-1-phenylethyl]amino]sulfonyl}amino)propionic acid
- Methyl (2S)-2-({[cyclopentyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2S)-2-({[cyclopentyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid

- 70 -


- Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-((isobutyl(isopropyl)amino)sulfonyl)amino)propionate
- (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-((isobutyl(isopropyl)amino)sulfonyl)amino)propionic acid
- Methyl (2S)-2-((cyclohexyl(isopropyl)amino)sulfonyl)amino)-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate
- (2S)-2-((cyclohexyl(isopropyl)amino)sulfonyl)amino)-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid
- Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-((isobutyl[(1R)-1-phenylethyl]amino)sulfonyl)amino)propionate
- (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-((isobutyl[(1R)-1-phenylethyl]amino)sulfonyl)amino)propionic acid
- Methyl (2S)-2-((methyl(phenyl)amino)sulfonyl)amino)-3-[4-(2,6-dichlorobenzoyl)amino]phenyl]propionate
- (2S)-2-((methyl(phenyl)amino)sulfonyl)amino)-3-[4-(2,6-dichlorobenzoyl)amino]phenyl]propionic acid
- Methyl (2S)-{[2-(phenylsulfonyl)phenyl]amino}sulfonyl)amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate
- (2S)-{[2-(phenylsulfonyl)phenyl]amino}sulfonyl)amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid

11) A process for producing a compound of formula I as defined in any one of claims 1 to 10, which process comprises reacting an amine of formula (III):



wherein Rd, R3, R4, R5, R6, L1 and n are as defined in any one of claims 1 to 10 with a corresponding sulfamoyl chloride of formula (IV):


- 71 -




(IV)

wherein R1 and R2 are as defined in any one of claims 1 to 10.

12) A process for producing a compound of formula I as defined in any one of claims 1 to 10, which process comprises reacting an amine of formula (IIa):




wherein Rd, R3, R4, R5, R6, L1 and n are as defined in any one of claims 1 to 10 with an amine of formula (V)




(V)

wherein R1 and R2 are as defined in any one of claims 1 to 10.

13) A process for producing a compound of formula I as defined in any one of claims 1 to 10, which process comprises reacting an amine of formula (III):



wherein R3, R4, R5, R6, Rd, L1 and n are as defined in any one of claims 1 to 10 with a sulfamide of formula (VII):




(VII)


wherein R1 and R2 are as defined in any one of claims 1 to 10.

14) A process for producing a compound of formula I as defined in any one of claims 1 to 10, which process comprises the steps of:


(a) reacting an amine of formula (III):




wherein  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_d$ ,  $L_1$  and  $n$  are as defined in any one of claims 1 to 10 with tert-butanol and chlorosulfonyl isocyanate to yield the sulfamide of formula (VIII); and



(b) reacting the sulfamide of formula (VIII) with an alcohol of formula (IX).




15) A process for producing a compound of formula I as defined in any one of claims 1 to 10, which process comprises reacting an amine of formula (X):



- 73 -

wherein Rd, R3, R4, R5, R6, L1 and n are as defined in any one of claims 1 to 10 with an amine of formula (V)



wherein R1 and R2 are as defined in any one of claims 1 to 10.

- 16) Use of a compound of formula I as defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pathological condition susceptible of being improved by antagonism of  $\alpha_4\beta_1$  and/or  $\alpha_4\beta_7$  integrins.
- 17) Use according to claim 16, wherein the medicament is for the treatment of a pathological condition susceptible of being improved by the inhibition or prevention of cell adhesion processes mediated by  $\alpha_4\beta_1$  and/or  $\alpha_4\beta_7$  integrins.
- 18) Use according to any one of claims 16 or 17, wherein the medicament is for the prevention or treatment of an immune or inflammatory disease or disorder susceptible of being improved by antagonism of  $\alpha_4\beta_1$  and/or  $\alpha_4\beta_7$  integrins.
- 19) Use according to any one of claims 16 to 18, wherein the pathological condition or disease is multiple sclerosis, asthma, allergic rhinitis, allergic conjunctivitis, an inflammatory lung disease, rheumatoid arthritis, polydermatomyositis, septic arthritis, type I diabetes, rejection following organ transplantation, restenosis, rejection following autologous bone marrow transplantation, inflammatory sequelae of viral infections, atopic dermatitis, myocarditis, inflammatory bowel disease including ulcerative colitis and Chron's disease, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, psoriasis, tumor metastasis, atherosclerosis or cerebral ischemia.
- 20) A pharmaceutical composition comprising an effective amount of a compound as defined in any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

- 21) A compound or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 10 for use in a method of treatment of a subject afflicted with a pathological condition susceptible to amelioration by antagonism of  $\alpha 4\beta 1$  and/or  $\alpha 4\beta 7$  integrins.
- 22) A method for treating a subject afflicted with a pathological condition susceptible to amelioration by antagonism of  $\alpha 4\beta 1$  and/or  $\alpha 4\beta 7$  integrins, which comprises administering to said subject an effective amount of a compound of formula I as defined in any one of claims 1 to 10.
- 23) A method according to claim 22, wherein the pathological condition is susceptible to amelioration by the inhibition or prevention of cell adhesion processes mediated by  $\alpha 4\beta 1$  and/or  $\alpha 4\beta 7$  integrins.
- 24) A method according to any one of claims 22 or 23, wherein the pathological condition is an immune or inflammatory disease or disorder susceptible to amelioration by antagonism of  $\alpha 4\beta 1$  and/or  $\alpha 4\beta 7$  integrins.
- 25) A method according to any one of claims 22 to 24, wherein the pathological condition or disease is multiple sclerosis, asthma, allergic rhinitis, allergic conjunctivitis, an inflammatory lung disease, rheumatoid arthritis, polydermatomyositis, septic arthritis, type I diabetes, rejection following organ transplantation, restenosis, rejection following autologous bone marrow transplantation, inflammatory sequelae of viral infections, atopic dermatitis, myocarditis, inflammatory bowel disease including ulcerative colitis and Chron's disease, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, psoriasis, tumor metastasis, atherosclerosis or cerebral ischemia.